Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
F 145.5 -2.77% -4.14
SGEN closed down 2.77 percent on Friday, April 16, 2021, on approximately normal volume.
Earnings due: Apr 28
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up
Historical SGEN trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
50 DMA Resistance Bearish -2.77%
Pocket Pivot Bullish Swing Setup -2.77%
Bollinger Band Squeeze Range Contraction -2.77%
Multiple of Ten Bearish Other -2.77%
BB Squeeze + Upper Band Touch Range Contraction -2.77%
Above Upper BB Strength -2.77%
Up 3 Days in a Row Strength -2.77%
Upper Bollinger Band Touch Strength -2.77%
Crossed Above 20 DMA Bullish 0.90%
Older End-of-Day Signals for SGEN ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support 1 day ago
Down 3% 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 1 ATR 1 day ago
Down 2 % 1 day ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Seattle Genetics, Inc. Description

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Solid Tumors Treatment Of Cancer Monoclonal Antibody Monoclonal Antibodies Lymphoma Genetics Prostate Cancer Chemotherapy Carcinoma Pancreatic Cancer Hematologic Malignancies Therapies For Cancer Antibody Drug Conjugates Renal Cell Carcinoma Resistant Prostate Cancer CD19 Hodgkin Lymphoma Non Hodgkin Lymphoma Castration Resistant Prostate Cancer Cd30 Chemotherapy Regimen Metastatic Pancreatic Cancer Positive Solid Tumors

Is SGEN a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 213.94
52 Week Low 134.51
Average Volume 1,168,827
200-Day Moving Average 170.29
50-Day Moving Average 151.52
20-Day Moving Average 142.97
10-Day Moving Average 144.19
Average True Range 5.10
ADX 18.0
+DI 23.58
-DI 19.81
Chandelier Exit (Long, 3 ATRs ) 136.59
Chandelier Exit (Short, 3 ATRs ) 149.80
Upper Bollinger Band 149.32
Lower Bollinger Band 136.61
Percent B (%b) 0.7
BandWidth 8.88
MACD Line -1.60
MACD Signal Line -2.79
MACD Histogram 1.1892
Fundamentals Value
Market Cap 26.04 Billion
Num Shares 179 Million
EPS 2.65
Price-to-Earnings (P/E) Ratio 54.95
Price-to-Sales 15.86
Price-to-Book 13.12
PEG Ratio -0.08
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 153.45
Resistance 3 (R3) 153.66 151.23 152.13
Resistance 2 (R2) 151.23 149.20 151.12 151.68
Resistance 1 (R1) 148.36 147.95 147.15 148.15 151.24
Pivot Point 145.93 145.93 145.32 145.82 145.93
Support 1 (S1) 143.06 143.90 141.85 142.85 139.76
Support 2 (S2) 140.63 142.65 140.52 139.32
Support 3 (S3) 137.76 140.63 138.88
Support 4 (S4) 137.55